Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The evidence that motivated an independent review of breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Elevated miR-9 in Cerebrospinal Fluid Is Associated with Poor Functional Outcome After Subarachnoid Hemorrhage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • kConFab investigators
Vis graf over relationer

Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients, the carriers of germline pathogenic variants in BRCA1 or BRCA2 genes. We found that rs57025206 was significantly associated with the overall survival, predicting higher mortality of BRCA1 carrier patients with estrogen receptor-negative breast cancer, with a hazard ratio 4.37 (95% confidence interval 3.03-6.30, P = 3.1 × 10-9). Multivariable analysis adjusted for tumor characteristics suggested that rs57025206 was an independent survival marker. In addition, our exploratory analyses suggest that the associations between genetic variants and breast cancer patient survival may depend on tumor biological subgroup and clinical patient characteristics.

OriginalsprogEngelsk
TidsskriftCurrent Medical Literature. Breast Cancer
Vol/bind6
Sider (fra-til)44
ISSN2374-4677
DOI
StatusUdgivet - 2020

Bibliografisk note

© The Author(s) 2020.

ID: 62074833